Deadline for manuscript submissions: 01 August 2021Print Special Issue Flyer (9)
Professor of Apply Physiology at Autonomous University of Barcelona, Chairman of Translational Research program on Acute Respiratory Failure and Sepsis, Barcelona, Spain
Interests: Intensive care, ARDS, Sepsis
Fifty Years Ago, Ashbaugh and colleagues described for the first time the term adult (later changed to acute) respiratory distress syndrome (ARDS). Since then substantial progress has been made in the care of affected patients and those at risk for the disorder, with reductions in both incidence and mortality. However, ARDS remains a relatively common and lethal or disabling syndrome. In the recent International study of LUNG SAFE involving 29,144 patients, 10% of all patients admitted to the intensive care unit and 23% of mechanically ventilated patients had ARDS. Mortality in the subgroup of patients with severe ARDS was 46%. Patients who survive this disorder are at high risk for cognitive decline, depression, post-traumatic stress disorder, and persistent skeletal-muscle weakness.
ARDS is a syndrome characterized by substantial heterogeneity. A much better understanding of biològic and genètic underpinnings of sub-phenotypes of ARDS should lead the way to move targeted therapies. Until then, ICU practices that prevent ARDS, early and effective treatment of the insults leading to ARDS, and long-protective ventilation and sensible fluid management remain the essential elements for good outcomes.
Novel therapeutics have largely failed to translate from promising preclinical findings into improved patients outcomes in late phase clinical trials. Recent advances in personalized medicine, big data, causal inference using observational data, novel clinical trial designs, preclinical disease modelin, and understanding of recovery from acute illness promise to transform the methods of pulmonary and critical care clinical research. The recommendations for future research priorities and directions are: 1) focusing on understanding the clinical, physiological, and biological underpinnings of heterogeneity in ARDS with the goal of developing targeted, personalized interventions; 2) optimizing preclinical models by incorporating comorbidities, cointerventions , and òrgan suport; 3) developing and applying novel clinical trial designs; 4) advancing mechanistic understanding of injury and recovery to develop and test interventions targeted at achieving long-term improvements in the lives of patients and famílies.
This special issue will review new insights in ARDS by International experts in intensive care and acute respiratory failure.
Acute respiratory distress syndrome (ARDS), Intensive care, Heterogeneity, Personalized interventions, Cointerventions, Incorporating comorbidities, Clinical trial
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access journal published by MRE Press. As of January 2021, Signa Vitae will change to a bimonthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.